B

Baroness Barker (LD)

Speaking in the House of Lords on 19 November 2026

Debate

Alzheimer’s Disease and Vascular Dementia

Contribution

My Lords, the noble Lord, Lord Jackson of Peterborough, and I come from very different schools of political thought, and we are usually on opposite sides of an argument, but not today. I hope that we can find common cause, not least because it is a privilege to follow the noble Lord, Lord Gascoigne. As some noble Lords know, I spent the last five years being a carer for somebody who had a very rare neurological condition. I have to say that one of the things that enabled me to cope was the fact that she did not develop dementia. Some people do. When you have to care for somebody who has a physical condition along with dementia, that is the hardest thing of all. That is what we forget sometimes when we do the analysis of what the NHS provides for people with dementia: we put that into a separate compartment from other conditions. Increasingly, when we are talking about people who are living well into old age—and even younger people—we are actually talking about people carrying a double burden. It was the case in times gone by that there was no treatment at all following a diagnosis. Today, we have some glimmers of hope. People have talked about various drugs, Lecanemab being one, and this latest development, AR1001, being another; they are not yet available on the NHS but they hold out some hope of either delaying the development of symptoms or affecting an underlying treatment. The noble Lord, Lord Gascoigne, is right. With the development of AI, neuroscientists are increasingly working on programmes that identify biomarkers in large populations of people, which are leading them to at least identify people who are likely to develop the disease as a first stage, if not then going to a cure. The pace at which all that research is happening means that within the foreseeable future, we will have effective drug interventions. One question that I want to ask the Minister is: what work is being done now to gauge the level of demand on the NHS? How are we going to deal with issues such as access to medication? Are we going to be in a position whereby drug treatments will be licensed but not provided on the NHS, and families may then wish to buy drugs that are known to be effective but are not affordable on the NHS? Those are key ethical issues that the NHS has to deal with. We owe it, not least to those people and their carers, because they are a group of people who have consistently been denied continuing healthcare. We have always said, “There is no treatment, therefore these people do not require nursing, therefore they are not eligible for continuing healthcare”. Yet, with their care needs, if they are left alone without support, they very quickly develop health needs simply by dint of being unable to manage their own personal health and well-being. I also want to ask the Minister about the Prime Minister’s statement. There is a lot of hope in the air. The Prime Minister’s Statement has given a lot of hope that we will finally have effective political focus on this somewhat overlooked area of medicine. The UK Dementia Research Institute is a very important part of that. Its scientists have for some time been looking not just at drug interventions but at the whole way in which technology can enable people to live well and safely, using monitoring and adaptions around their house. The announcement of the £48 million is very welcome. However, can the Minister say exactly what that is going to go to? Many of the speeches that noble Lords have made have pointed to one thing. Even if you are somebody like me, who knows the NHS very well, finding your way around it and dealing with the different elements of care, some of which are great but are just disparate and unconnected, means that if there is a care pathway, the carer is in charge of it, not anybody else. Other people are making good interventions, but they are not putting it all together. I do not think we have yet fully understood the role that carers play in care management, could play in care planning and should play in directing some of the research. They are the people who watch patients day to day and are in a position to input some of the things that used to be called observation. The worst thing in a carer’s life is to have a health professional say that the person they care for has to go to A&E. That never works out well at all. There is one important thing that we could do in this country: we could teach and equip every carer to do simple observations—temperature, blood pressure and oxygen levels. If we did that, we might well be able to stop a lot of unnecessary A&E admissions, admissions that scare the life out of a person who has dementia, and worry their carers just as much because they know they are in the wrong place. We are at a time of great potential and great hope. I would like the Minister to tell us, as much as she can, whether some of that money will go to the voluntary sector to help them to pull many of these good initiatives together for individual people.

More from Baroness Barker (LD)

Other recent Hansard contributions by the same speaker.

About Hansard

Hansard is the official verbatim record of proceedings in the UK Parliament. Every word spoken in the Commons and Lords is recorded and published — this page is a single contribution from that record.